Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173862 | 0.94 | FAAH (0.50) | GPR119FAAHKDM4EPKMIDO1 | |
| SCHEMBL31173859 | 0.94 | FAAH (0.50) | GPR119FAAHKDM4EPKMIDO1 | |
| SCHEMBL1581892 | 0.89 | FPR2 (0.48) | GPR119FAAHKDM4EPKMFPR2 | |
| SCHEMBL25269372 | 0.86 | P2RX7 (0.47) | GPR119FAAHKDM4EPKMP2RX7 | |
| SCHEMBL15939449 | 0.86 | GPR119 (0.46) | GPR119FAAHKDM4EPKMP2RX7 | |
| SCHEMBL1581610 | 0.83 | CHRM2 (0.42) | GPR119 | |
| SCHEMBL24493286 | 0.83 | GPR119 (0.48) | GPR119FAAH | |
| SCHEMBL16012151 | 0.81 | FAAH (0.50) | GPR119FAAHKDM4EPKM | |
| SCHEMBL22776955 | 0.80 | USP30 (0.50) | GPR119FAAHKDM4EPKMP2RX7 | |
| SCHEMBL31565576 | 0.80 | GPR119 (0.43) | GPR119PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025081082-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-116648248-B | Aromatic compound, pharmaceutical composition containing same and application thereof | 成都茵创园医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-116648248-A | Aromatic compound, pharmaceutical composition containing same and application thereof | 成都茵创园医药科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | GPR119 245/4885FAAH 2825/4885KDM4E 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.